- Does hpv throat cancer spread
- Replicazione del papilloma virus
- One of the major tools to evaluate this type of pathology is the neuroendocrine markers as chromogranin A, serotonin, urinary 5-hydroxy indolacetic acid, and neuron specific enolase.
- Que son parasitos oxiuros
- Он пожал ее руку.
- Virus del papiloma humano causas sintomas tratamiento y prevencion
Они сейчас здесь появятся.
- Helminth definitive host
Artikelempfehlungen Abstract The neuroendocrine neuroendocrine cancer age NETs are more frequent during the last decades. One of the major tools to evaluate this type of pathology is the neuroendocrine markers as chromogranin A, serotonin, urinary 5-hydroxy indolacetic acid, and neuron specific enolase.
Revista Romana de Medicina de Laborator
They change related to the disease progression, regardless therapy. Some of the drugs that are used for NETs as somatostatin analogs for example octreotide might interfere with glucose metabolism.
We analyzed in a retrospective study neuroendocrine cancer age 2 years the dynamic of the NET markers and the glycemia profile. Material and Methods. All the patients had at least one assay per year.
Neuroendocrine cancer age dose of octreotide varied from 20 to 50 mg, monthly. The fasting glucose insignificantly changed from baseline after 2 years. No new case of diabetes was registered. One case of known diabetes needed insulin but interferon therapy was also added during this time period.
Services on Demand
The chromogranin A had sustained high values for all the 9 cases, marking the disease progression. The neuron specific enolase significantly increased, and the serum serotonin as well as the 5HIIA was much higher in 2 cases with aggressive carcinoid symptoms. The NET markers and the glucose metabolism are most useful tools in the management of NETs, yet they are not neuroendocrine cancer age.
Accepted Apr Copyright © The Authors. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Neuroendocrine tumors. Endocr Relat Cancer.
Most Downloaded Articles
DOI: Oberndorfer S. Karzinoide tumoren des dunndarms.
MATERIALS AND METHODS: Imaging studies of 22 patients 12 men, mean age 60 years with histopathologically confirmed diagnosis, evaluated in the authors's institution during the last five years were retrospectively reviewed by two radiologists, neuroendocrine cancer age findings being consensually described focusing on changes observed at computed tomography. Only one typical carcinoid presented the characteristic appearance of central endobronchial nodule with distal pulmonary atelectasis, while the others were pulmonary nodules or masses. The atypical carcinoids corresponded to peripheral heterogeneous masses. One out of the three LCNCs was a peripheral homogeneous mass, while the others were ill-defined and heterogeneous. The 11 SCLCs corresponded to central, infiltrating and heterogeneous masses with secondary pleuropulmonary changes.
Frank Z Pathol. Carcinoid Tumors. Bellizzi AM. Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnosis immunohistochemistry.
Adv Anat Pathol. Chromogranins A B C: widespread consitituents of secretory vesicles.
Ann N Y Acad Sci. Chromogranin A neuron specific enolase carcinoembryonic antigen and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. CO; 8.
Regul Pept. The poor prognosis factors in G2 neuroendocrine tumor.
Rom J Morphol Embryol. The dedifferentiation of neuroendocrine tumor metastases: myth or reality?
Octreotide for the treatment of hypoglycemia after insulin glargine overdose. J Emerg Med.
- Какая правда.
Biochemical testing for neuroendocrine tumors. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors.
Endocrinol Metab Clin North Am ;40 1 Well-differentiated neuroendocrine tumor and osteoporosis: incidental finding? Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide. Acta Oncol.
Long-term clinical outcome of somatostatin analogues for treatment of pregressive metastatic well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol. Predictive factors neuroendocrine cancer age efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma.